Shoemaker Mary Teresa 4

What Happened
Mary Teresa Shoemaker, a director of Traws Pharma, received an award of 33,435 stock options on 2026-03-08. The Form 4 reports the acquisition as a derivative award with an acquisition price of $0.00 (i.e., an option grant rather than a cash purchase of shares). No immediate sale or exercise was reported.

Key Details

• Transaction date: 2026-03-08; Form 4 filed: 2026-03-10 (appears timely; Form 4 due within two business days).
• Instrument: Stock options (derivative) — 33,435 options; reported acquisition price $0.00.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: Awarded under the Issuer’s 2021 Incentive Compensation Plan (per F1). The options vest 100% on the first anniversary of the grant date; the compensation committee that approved the grant consists of independent directors.
• No indication of immediate exercise, cashless sale, or a 10b5-1 plan in the filing excerpt.

Context
This was a compensation grant (option award) rather than an open-market purchase or sale. Option grants give the holder the right to buy shares later (subject to vesting and exercise terms); they do not represent immediate share ownership or cash proceeds. For retail investors, such grants are routine director compensation and do not by themselves indicate a buy or sell decision.